Data Review From the Phase III DISCOVER-2 Trials

Join Jessica Farrell, PharmD, clinical pharmacist at Albany Medical Center, as she explores key findings from the Phase 3 DISCOVER-2 trial, which evaluates the long-term efficacy and safety of Guselkumab in biologic-naïve patients with active psoriatic arthritis (PsA).

The trial demonstrates sustained clinical improvements in PsA symptoms through Week 100, with low rates of radiographic progression and serious adverse events. These findings highlight Guselkumab’s durable response, reinforcing its role as a long-term treatment option for patients with PsA.

Understanding the impact of IL-23 inhibition in psoriatic disease is essential for APPs and clinicians managing autoimmune conditions. Learn more about the latest clinical data and best practices in PsA treatment by visiting the RhAPP website or attending the RhAPP Annual Conference for expert insights.

For more expert insights and the latest advancements in rheumatology, download the RhAPP ACE App for valuable resources and clinical updates.